Literature DB >> 27031009

Cell and gene therapy strategies to eradicate HIV reservoirs.

Chelsea Spragg1, Harshana De Silva Feelixge, Keith R Jerome.   

Abstract

PURPOSE OF REVIEW: Highly active antiretroviral treatment has dramatically improved the prognosis for people living with HIV by preventing AIDS-related morbidity and mortality through profound suppression of viral replication. However, a long-lived viral reservoir persists in latently infected cells that harbor replication-competent HIV genomes. If therapy is discontinued, latently infected memory cells inevitably reactivate and produce infectious virus, resulting in viral rebound. The reservoir is the biggest obstacle to a cure of HIV. RECENT
FINDINGS: This review summarizes significant advances of the past year in the development of cellular and gene therapies for HIV cure. In particular, we highlight work done on suppression or disruption of HIV coreceptors, vectored delivery of antibodies and antibody-like molecules, T-cell therapies and HIV genome disruption.
SUMMARY: Several recent advancements in cellular and gene therapies have emerged at the forefront of HIV cure research, potentially having broad implications for the future of HIV treatment.

Entities:  

Mesh:

Year:  2016        PMID: 27031009      PMCID: PMC4913694          DOI: 10.1097/COH.0000000000000284

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  84 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.

Authors:  Renier Myburgh; Sandra Ivic; Michael S Pepper; Gustavo Gers-Huber; Duo Li; Annette Audigé; Mary-Aude Rochat; Vincent Jaquet; Stephan Regenass; Markus G Manz; Patrick Salmon; Karl-Heinz Krause; Roberto F Speck
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

3.  CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Authors:  Timothy J Henrich; Emily Hanhauser; Linda J Harrison; Christine D Palmer; Marisol Romero-Tejeda; Stephanie Jost; Ronald J Bosch; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2015-10-28       Impact factor: 5.226

4.  Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Authors:  Qi Zhou; Katharina M Uhlig; Anke Muth; Janine Kimpel; Camille Lévy; Robert C Münch; Janna Seifried; Anett Pfeiffer; Alexandra Trkola; Cheick Coulibaly; Dorothee von Laer; Winfried S Wels; Udo F Hartwig; Els Verhoeyen; Christian J Buchholz
Journal:  J Immunol       Date:  2015-07-31       Impact factor: 5.422

5.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

6.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

7.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Authors:  Matthew R Gardner; Lisa M Kattenhorn; Hema R Kondur; Markus von Schaewen; Tatyana Dorfman; Jessica J Chiang; Kevin G Haworth; Julie M Decker; Michael D Alpert; Charles C Bailey; Ernest S Neale; Christoph H Fellinger; Vinita R Joshi; Sebastian P Fuchs; Jose M Martinez-Navio; Brian D Quinlan; Annie Y Yao; Hugo Mouquet; Jason Gorman; Baoshan Zhang; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton; Peter D Kwong; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers; David T Evans; Beatrice H Hahn; Alexander Ploss; Paula M Cannon; Michael S Seaman; Michael Farzan
Journal:  Nature       Date:  2015-02-18       Impact factor: 49.962

8.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

9.  AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity.

Authors:  Sebastian P Fuchs; José M Martinez-Navio; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers
Journal:  PLoS Pathog       Date:  2015-08-06       Impact factor: 6.823

10.  CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.

Authors:  Gang Wang; Na Zhao; Ben Berkhout; Atze T Das
Journal:  Mol Ther       Date:  2016-01-22       Impact factor: 11.454

View more
  10 in total

1.  Disruption or Excision of Provirus as an Approach to HIV Cure.

Authors:  Keith R Jerome
Journal:  AIDS Patient Care STDS       Date:  2016-11-17       Impact factor: 5.078

2.  Tuning DNA binding affinity and cleavage specificity of an engineered gene-targeting nuclease via surface display, flow cytometry and cellular analyses.

Authors:  Nixon Niyonzima; Abigail R Lambert; Rachel Werther; Harshana De Silva Feelixge; Pavitra Roychoudhury; Alexander L Greninger; Daniel Stone; Barry L Stoddard; Keith R Jerome
Journal:  Protein Eng Des Sel       Date:  2017-07-01       Impact factor: 1.650

3.  Role of Tunneling Nanotube-like Structures during the Early Events of HIV Infection: Novel Features of Tissue Compartmentalization and Mechanism of HIV Spread.

Authors:  George Okafo; Silvana Valdebenito; Maribel Donoso; Ross Luu; David Ajasin; Brendan Prideaux; Santhi Gorantla; Eliseo A Eugenin
Journal:  J Immunol       Date:  2020-10-09       Impact factor: 5.422

4.  Why cure, why now?

Authors:  Daniel R Kuritzkes
Journal:  J Med Ethics       Date:  2016-06-07       Impact factor: 2.903

Review 5.  Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.

Authors:  Sheraz Khan; Mazhar Iqbal; Muhammad Tariq; Shahid M Baig; Wasim Abbas
Journal:  Clin Epigenetics       Date:  2018-02-05       Impact factor: 6.551

Review 6.  Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.

Authors:  Wei Xu; Haoyang Li; Qian Wang; Chen Hua; Hanzhen Zhang; Weihua Li; Shibo Jiang; Lu Lu
Journal:  Biomed Res Int       Date:  2017-04-26       Impact factor: 3.411

7.  Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA.

Authors:  Christina K Psomas; Alain Lafeuillade; David Margolis; Karl Salzwedel; Mario Stevenson; Nicolas Chomont; Guido Poli; Jean-Pierre Routy
Journal:  J Virus Erad       Date:  2018-04-01

Review 8.  Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.

Authors:  Annika M Frank; Christian J Buchholz
Journal:  Mol Ther Methods Clin Dev       Date:  2018-10-17       Impact factor: 6.698

9.  Revisiting the 'sterilising cure' terminology: a call for more patient-centred perspectives on HIV cure-related research.

Authors:  Luke Newton; Raúl Necochea; David Palm; Jeff Taylor; Liz Barr; Hursch Patel; Anshula Nathan; Jo Gerrard; Laurie Sylla; Brandon Brown; Karine Dubé
Journal:  J Virus Erad       Date:  2019-04-01

10.  Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.

Authors:  Pavitra Roychoudhury; Harshana De Silva Feelixge; Daniel Reeves; Bryan T Mayer; Daniel Stone; Joshua T Schiffer; Keith R Jerome
Journal:  BMC Biol       Date:  2018-07-11       Impact factor: 7.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.